Listing & Compliance Notices

MSP Recovery, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“November 28, 2025, the Company received an additional staff determination letter (“Additional Staff Determination”) indicating that the bid price of the Company’s listed securities has closed at less than $1 per share over the previous 30 consecutive business days, and, as a result, the Company is not in compliance with Listing Rule 5550(a)(2). The Staff determined that such non-compliance served as an additional basis for delisting the Company’s securities from Nasdaq. The Company will be afforded an opportunity to present its views to the Panel with respect to this additional deficiency at t”

MSP Recovery, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“October 22, 2025, the Company received a Staff Delisting Determination (the “Delisting Notification”), notifying the Company that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market, under Listing Rule 5550(b)(1), as the Company’s stockholders’ equity reported in the Company’s Form 10-K for the year ended December 31, 2024, was below the required minimum of $2.5 million, and the Company did not meet the alternative compliance standards, relating to the market value of listed securities of $35 million or net income from c”

Laser Photonics Corp received a nasdaq deficiency notice notice regarding late filing.

“November 20, 2025, the registrant (“Laser Photonics” or the “Company”) received a notice from Nasdaq Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that since it had not received the Company’s Form 10-Q for the period ended September 30, 2025, the Company does not comply with Nasdaq’s Listing Rules for continued listing. Nasdaq stated that the Company has until January 19, 2026, to submit a plan to regain compliance with respect to this delinquent report. Nasdaq can grant an exception to allow the Company to regain compliance up to a maximum of 180 calendar”

TREASURE GLOBAL INC received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv)).

“December 2, 2025, Treasure Global Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff has determined to delist the Company’s securities from The Nasdaq Capital Market (the “Staff Determination”). The Staff Determination was issued because (i) the Company failed to comply with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), and (ii) pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible to receive a compliance period due to having effected”

AI Financial Corp received a nasdaq noncompliance notice notice regarding audit committee (rules 5605(c)).

“December 3, 2025, the Company received a notice from The Nasdaq Stock Market LLC (the “ Notice ”), notifying the Company that, as a result of the Resignation, the Company is not in compliance with the requirements under Nasdaq Listing Rule 5605 (the “ Corporate Governance Requirements ”), specifically Nasdaq Listing Rule 5605(c), which requires, among other things, that the Company have an Audit Committee that has at least three members, each of whom must (i) be an independent, (ii) meet the criteria for independence set forth in Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, as a”

GRI Bio, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 26, 2025, the Company received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market (the “Notice”) based on the information provided in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. Nasdaq Listing Rule 5550(b)(1) requires that companies listed on The Nasdaq Capital Market with a market value of listed securities of less than $35,000,000 and a”

Vestand Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 25, 2025, Vestand Inc. (the “Company”) received a notice (the “Notice”) from Nasdaq Listing Qualifications (“Nasdaq”) notifying the Company that as it has not yet filed its Quarterly Report on Form 10-Q for the period ended September 30, 2025 (the “Form 10-Q”), the Company no longer complies with Listing Rule 5250(c)(1) for continued listing on Nasdaq. The Company has 60 calendar days to submit to Nasdaq a plan to regain compliance, and if such plan is accepted, Nasdaq may grant the Company an extension of up to 180 calendar days from the prescribed due date for filing the Form 10-Q”

Israel Acquisitions Corp received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).

“November 25, 2025, the Company received a delist determination letter from the Staff (the “ Nasdaq Notice ”) advising the Company that the Staff had determined that the Company had not satisfied the conditions set forth in the Staff’s MVLS Notice to regain compliance with the MVLS Requirement. Accordingly, the Staff indicated that unless the Company requests a hearing panel appeal of the delist determination by December 2, 2025, its securities would be delisted on December 4, 2025. In connection with the delisting and suspension, Nasdaq has advised that it will complete the delisting by filing”

Oak Woods Acquisition Corp received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“November 19, 2025, Oak Woods Acquisition Corporation (the “ Company ”) received a letter (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the Company no longer meets the minimum standard for Nasdaq Listing Rule 5550(b)(2), which requires listed companies on the Nasdaq Capital Market to maintain a minimum Market Value of Listed Securities (“MVLS”) of $35 million. The notification letter stated that the Company’s MVLS had been below $35 million for the last 30 consecutive business days from the date of the letter”

ScanTech AI Systems Inc. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

“he opening of business on December 5, 2025, and Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission (“SEC”). The Company has requested a hearing before the Nasdaq Hearings Panel and paid the associated fee. Because the Notice cites non-compliance with Nasdaq Listing Rule 5250(c)(1) as an additional basis for the Staff determination, the Company expects to receive an automatic 15-day stay of suspension under Nasdaq Listing Rule 5815(a)(1)(B) in connection with that deficiency. The Company has also submitted a request for an extended stay of suspension applicable to t”

ScanTech AI Systems Inc. received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(A)).

“he opening of business on December 5, 2025, and Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission (“SEC”). The Company has requested a hearing before the Nasdaq Hearings Panel and paid the associated fee. Because the Notice cites non-compliance with Nasdaq Listing Rule 5250(c)(1) as an additional basis for the Staff determination, the Company expects to receive an automatic 15-day stay of suspension under Nasdaq Listing Rule 5815(a)(1)(B) in connection with that deficiency. The Company has also submitted a request for an extended stay of suspension applicable to t”

Cambium Networks Corp received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 25, 2025, Cambium Networks Corporation (the “Company”) received an additional staff determination letter (“Staff Determination Letter”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company it was not in compliance with Nasdaq’s continued listing standards as set forth in Listing Rule 5250(c)(1) (the “Filing Rule”), given the Company’s inability to timely file its Quarterly Report on Form 10-K for the period ended September 30, 2025 (“Q3 2025 Delinquent Filing” and together with the prior delinquent filings referenced”

BRC Group Holdings, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1), 5810(b)).

“November 21, 2025, B. Riley Financial, Inc. (the “Company”) received an expected delinquency notification letter from Nasdaq, pursuant to Nasdaq Listing Rule 5810(b). The letter indicated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Filing Rule”) as a result of the delayed filing of the Company’s Form 10-Q for the period ended September 30, 2025 (the “Third Quarter 10-Q”). As previously disclosed on November 19, 2025, the Company participated in a hearing with a Nasdaq Hearings Panel (the “Panel”) on November 4, 2025 in connection with the Company’s non-comp”

zSpace, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“November 25, 2025, zSpace, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the continued listing requirement set forth in Nasdaq Listing Rule 5550(b)(2), which requires listed companies to maintain a minimum market value of listed securities (“MVLS”) of at least $35,000,000. Based on the Staff’s review of the Company’s MVLS, the Company’s MVLS was below $35 million for the previous 30 consecutive business days. The Notice has no”

Laser Photonics Corp received a nasdaq deficiency notice notice regarding late filing.

“November 20, 2025, the registrant (“Laser Photonics” or the “Company”) received a notice from Nasdaq Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that since it had not received the Company’s Form 10-Q for the period ended September 30, 2025, the Company does not comply with Nasdaq’s Listing Rules for continued listing. Nasdaq stated that the Company has until January 19, 2026, to submit a plan to regain compliance with respect to this delinquent report. Nasdaq can grant an exception to allow the Company to regain compliance up to a maximum of 180 calendar”

P3 Health Partners Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 21, 2025, P3 Health Partners Inc. (the “Company”) received a letter (the “Letter”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), which notified the Company that it does not presently comply with Nasdaq’s Listing Rule 5550(b)(1) (the “Listing Rule”), which requires that the Company maintain a minimum of $2.5 million in stockholders’ equity, and that the Company also does not meet the alternatives of market value of listed securities or net income from continuing operations set forth in the Listing Rule. The Letter does”

Trailblazer Merger Corp I received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).

“November 25, 2025,Trailblazer Merger Corporation I (the “ Company ”) received a letter from Nasdaq (the “ Notice ”) which notified the Company that, for 30 consecutive business days, the Company’s market value of listed securities (“ MVLS ”) closed below the $50,000,000 MVLS threshold required for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(2)(A) (the “ MVLS Rule ”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has 180 calendar days, or until May 24, 2026 (the “ MVLS Compliance Period ”), to regain compliance with the MVLS Rule. The Noti”

Fusemachines Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“November 24, 2025, Fusemachines Inc., a Delaware corporation (the “ Company ”) received an expected letter (the “ Nasdaq Letter ”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 (the “ Quarterly Report ”), the Company was not in compliance with the timely filing requirements for continued listing under Nasdaq Listing Rule 5250(c)(1). The Nasdaq Letter has no immediate effect on the listing or trading of the Company’s common”

Algorhythm Holdings, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 28, 2025, Algorhythm Holdings, Inc. (the “Company”) received a letter from the Staff of the Nasdaq Stock Market, LLC indicating that the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 (the “Form 10-Q”), did not satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum stockholders’ equity of $2,500,000 (the “Stockholders’ Equity Requirement”). As reported in its Form 10-Q, the Company’s stockholders’ equity as of September 30, 2”

Protagenic Therapeutics, Inc.new received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 20, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter (the “Notice” ) from the Nasdaq Listing Qualifications Staff (the “Staff” ) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1) (minimum stockholders’ equity of $2,500,000) and Nasdaq Listing Rule 5250(c)(1) (timely filing of periodic reports). As reported in the Company’s Transition Report on Form 10-QT for the period ended June 30, 2025, the Company’s stockholders’ equity no longer satisfies the minimum requirement of Rule 5550(b)(1). The Staff also cited the Compa”

Protagenic Therapeutics, Inc.new received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 20, 2025, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter (the “Notice” ) from the Nasdaq Listing Qualifications Staff (the “Staff” ) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1) (minimum stockholders’ equity of $2,500,000) and Nasdaq Listing Rule 5250(c)(1) (timely filing of periodic reports). As reported in the Company’s Transition Report on Form 10-QT for the period ended June 30, 2025, the Company’s stockholders’ equity no longer satisfies the minimum requirement of Rule 5550(b)(1). The Staff also cited the Compa”

GT Biopharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“November 20, 2025, GT Biopharma, Inc. (the “Company”) received a letter (the “Letter”) from the Nasdaq Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its common stock, $0.001 par value per share (the “Common Stock”) had closed below $1 per share for 30 consecutive business days and, as a result, the Company was not in compliance with the $1 minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). This Letter has no immed”

SYNLOGIC, INC. received a nasdaq delisting notice notice regarding other.

“November 21, 2025, Synlogic, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that stated the Staff’s belief that the Company is a “public shell” and that, therefore, the continued listing of its securities is no longer warranted in the view of the Staff. In the Notice, the Staff explained that it based this belief on its review of the Company’s public disclosures and materials submitted to the Staff by the Company. In addition, the Staff noted its belief is supported by the Company’s lack o”

Akari Therapeutics Plc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“November 24, 2025, Akari Therapeutics, Plc (the “Company”) was notified (the “Notification Letter”) by the Nasdaq Listing Qualifications (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive busines”

Genprex, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

“November 25, 2025, the Company was formally notified that (i) the Panel determined that the Company has regained compliance with the Bid Price Requirement; and (ii) the Panel has also approved the Company’s request for an exception until December 31, 2025 to demonstrate long-term compliance with the Stockholders’ Equity Requirement (as extended, the “Exception”). As previously disclosed, upon request by the Company, the Panel has discretion to grant the Company continued listing through February 9, 2026. Pursuant to the Exception, the Company is required to, and fully intends to, provide the”

Genprex, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“November 25, 2025, the Company was formally notified that (i) the Panel determined that the Company has regained compliance with the Bid Price Requirement; and (ii) the Panel has also approved the Company’s request for an exception until December 31, 2025 to demonstrate long-term compliance with the Stockholders’ Equity Requirement (as extended, the “Exception”). As previously disclosed, upon request by the Company, the Panel has discretion to grant the Company continued listing through February 9, 2026. Pursuant to the Exception, the Company is required to, and fully intends to, provide the”

MetaVia Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5810(c)(3)(A)).

“November 26, 2025, the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to May 26, 2026 to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). The Company intends to continue actively monitoring the closing bid price for the Company’s common stock between now and May 26, 2026, and will consider available options to resolve the deficiency, including effecting a reverse stock split as stated above, and regain compliance with the Minimum Bid Price Requirement. If the Company does not re”

MetaVia Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“May 29, 2025, MetaVia Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) informing the Company that because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company had a period”

Spire Global, Inc. received a nyse noncompliance notice notice regarding late filing (rules 802.01E).

“November 25, 2025, Spire Global, Inc. (the “Company”) received written notice from the New York Stock Exchange (the “NYSE”) that the Company is not in compliance with the NYSE’s continued listing standards as set forth in Section 802.01E of the NYSE Listed Company Manual due to the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 (the “Form 10-Q”) with the Securities and Exchange Commission (the “SEC”) prior to November 19, 2025, the end of the extension period provided by Rule 12b-25 under the Securities Exchange Act of 1934, as amend”

Classover Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“November 21, 2025, Classover Holdings, Inc. (the “Company”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that, for the prior 30 consecutive business days (through November 20, 2025), the bid price of the Company’s Class B Common Stock, $0.0001 par value per share (“Common Stock”), had been below the minimum bid price of $1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2). The notice stated that the Company would be afforded 180 calendar days (until May 20, 2026) to regain complianc”

BROADWAY FINANCIAL CORP \DE\ received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 20, 2025, Broadway Financial Corporation (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the periodic financial reporting requirements set forth in Nasdaq Listing Rule 5250(c)(1) (“Rule 5250(c)(1)”) for continued listing on The Nasdaq Capital Market because its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 (the “Q3 Form 10-Q”) was not filed within the time period prescribed by the Securities and Exchange Commission (“SEC”) rules. The Notice has no immed”

Iveda Solutions, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1), 5550(b)(2), 5550(b)(3)).

“May 27, 2025, Iveda Solutions, Inc. (the “Company”) received a letter from The Nasdaq Listing Qualifications Department (the “Staff”) indicating that it did not comply with Nasdaq Listing Rules 5550(b)(1), 5550(b)(2), or 5550(b)(3) (the “Rules”) which require companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity, or $35 million market value of listed securities, or $500,000 of net income from continuing operations, for continued listing. On November 25, 2025, the Company received additional correspondence from the Staff advising that, based o”

Clearside Biomedical, Inc. received a nasdaq noncompliance notice notice regarding market value (rules 5450(b)(2)(A)).

“August 28, 2025, the Company received written notice (the “ MVLS Notice ”) from Nasdaq notifying the Company that it is not in compliance with the minimum Market Value of Listed Securities of $50,000,000 required for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(A). In the Delisting Notice, the staff of Nasdaq referenced concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq, specifically referencing that certain MVLS Notice. Trading of the Common Stock will be suspended at the opening of”

Clearside Biomedical, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“November 24, 2025, the Company received written notice (the “ Delisting Notice ”) from the staff of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, as a result of the Case and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq has determined that the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), will be delisted from Nasdaq. In addition, as previously disclosed, on August 28, 2025, the Company received written notice (the “ MVLS Notice ”) from Nasdaq notifying the Company that it is not in compliance with t”

ARTELO BIOSCIENCES, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“ndicated that unless the Company requests a hearing panel appeal of the delist determination by November 26, 2025, its securities would be delisted on December 1, 2025. The Company intends to appeal Nasdaq’s determination to a hearing panel pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series to stay any further delisting actions through the hearing or any extension the hearings panel provides. Following the appeal request, the Company’s common stock, par value $0.001 per share, will continue to trade on Nasdaq under the symbol “ARTL.” 2 SIGNATURES Pursuant to the requir”

Envoy Medical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“November 19, 2025, Envoy Medical, Inc. (the “Company”) received a staff determination notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), informing the Company that its Class A Common Stock, par value $0.0001 per share (the "Common Stock"), has failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) for the 30 consecutive business days prior to the date of the Notice. The Notice has no immediate effect on the listing of the Common Stock on The Nasda”

Liminatus Pharma, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C)).

“November 19, 2025, Liminatus Pharma, Inc. (the “Company”) received notices from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company was no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum Market Value of Listed Securities (MVLS) of $50,000,000 (the “MVLS Rule”), based upon a review of the Company’s MVLS for the last 30 consecutive business days and (ii) Nasdaq Listing Rule 5450(b)(2)(C) due to its failure to maintain a minimum Market Value of Publicly Held Shares (MVPHS) of $15,000,000 (”

Singularity Future Technology Ltd. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“November 19, 2025, Singularity Future Technology Ltd. (the “Company”) received a staff determination notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), informing the Company that its common stock, no par value (the “Common Stock”), fails to comply with the $1 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) for the 30 consecutive business days prior to the date of the Notice. Nasdaq’s notice has no immediate effect on the listing of the Common Stock on The Nasdaq Capital M”

AMERICAN REBEL HOLDINGS INC received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

“November 21, 2025, the Company received a compliance letter from the Nasdaq Hearings Panel (“ Panel ”) confirming the Company is in compliance with Nasdaq Listing Rule 5550(b)(1) (the “ Equity Rule ”). In its November 21, 2025 letter, the Panel advised that, based on the Nasdaq Listing Qualifications Staff’s compliance worksheet, American Rebel has satisfied the exception previously granted under the Equity Rule. Under Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject to a mandatory one-year Panel monitoring period beginning on the date of the letter. If, within the one-year monit”

urban-gro, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“August 28, 2025 due to the Company’s non-compliance with (i) Nasdaq Listing Rule 5550(a)(2) due to the Company’s common stock having had a bid price of less than $1.00 per share for 30 consecutive business days (the “Bid Price Rule”), (ii) Nasdaq Listing Rule 5250(c)(1) due to the Company’s delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and its Quarterly Reports on Form 10-Q for the periods ended March 31, 2025 and June 30, 2025 (the “Timely Filing Requirement”), and (iii) Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain minimum”

urban-gro, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 18, 2025, the Company received a determination letter (the “Letter”) from Nasdaq stating that because the Company did not timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2025, the resulting filing delinquency would be an additional basis for delisting the Company’s securities pursuant to the Timely Filing Requirement. The Letter notified the Company that the Panel would consider the matter in their decision regarding the Company’s continued listing on the Nasdaq Capital Market, and requested that the Company present its views with respect to the additi”

SunPower Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“November 19, 2025, the Company received an expected letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the quarter ended September 28, 2025 (the “Q3 Form 10-Q”), the Company was not in compliance with the timely filing requirements for continued listing under Nasdaq Listing Rule 5250(c)(1). The Nasdaq letter has no immediate effect on the listing or trading of the Company’s common stock or warrants. The Company’s Form 12b-25 notice (the “Form 12b-25”) filed wi”

DevvStream Corp. received a nasdaq deficiency notice notice regarding other (rules 5550(b)(3)).

“November 18, 2025, DevvStream Corp. (the “ Company ”) received a notification letter (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that its net income from continuing operations had fallen below the minimum requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(3) (the “ Minimum Net Income Requirement ”) and that the Company does not meet the alternatives of market value of listed securities or stockholders’ equity (collectively with the Minimum Net Income Requirement, th”

Traeger, Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“lure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On Novembe r 19, 2025 , Traeger, Inc. (the “Company”) received written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is not in compliance with the continued listing standard set forth in Section 802.01C of the NYSE’s Listed Company Manual (“Section 802.01C”) because the average closing price of the Company’s common stock was less than $1.00 per share over a consecutive 30 trading-day period ended November 14, 2025. The Notice does not result in the immediate delisting of the Company’s commo”

AIxCrypto Holdings, Inc. received a nasdaq noncompliance notice notice regarding other (rules 5635(b)).

“November 18, 2025, the Company received a letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it failed to comply with Nasdaq’s shareholder approval requirements set forth in Nasdaq Listing Rule 5635(b) (the “Rule”), which requires shareholder approval prior to the issuance of securities when the issuance or potential issuance will result in a change of control of the Company, in connection with the Company’s private placement transaction (the “PIPE Financing”) that closed on September 29. 2025 (the”

iSpecimen Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“November 19, 2025, iSpecimen Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price of the Company’s common stock had been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for the prior 30 consecutive business days. As a result, the Company is no longer in compliance with the Minimum Bid Price Requirement. The Notice has no”

Avalon GloboCare Corp. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 19, 2025, the Company received a letter (the “November Nasdaq Letter”) from Nasdaq indicating that the Company was not in compliance with Listing Rule 5550(b). Unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”), trading of the Company’s common stock would be subject to suspension/delisting. Accordingly, the Company plans to timely request a hearing before the Panel, which request will automatically stay any suspension or delisting action by Nasdaq pending the hearing and the expiration of any additional extension period granted by the Panel fol”

Moleculin Biotech, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 20, 2025, the Company received a delist determination letter from the Staff (the “Nasdaq Notice”) advising the Company that the Staff had determined that the Company had not regained compliance with the Listing Rule. Accordingly, the Staff indicated that unless the Company requests a hearing panel (a “Panel”) appeal of the delist determination by November 28, 2025, its securities would be delisted on December 2, 2025. The Company intends to appeal Nasdaq’s determination to a Panel pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series to stay any suspension pendin”

Triller Group Inc. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

“November 17, 2025, the Company received an additional delisting determination letter (the “Additional Determination Letter”) from the Staff of Nasdaq indicating that since it failed to timely file its Form 10-Q for the period ended September 30, 2025, this serves as an additional basis for delisting. As required under Nasdaq Listing Rule 5810(b), the Company issued a press release on November 21, 2025, announcing that it had received the Additional Determination Letter. A copy of this press release is attached as Exhibit 99.1 to this Form 8-K.”

TOMI Environmental Solutions, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 21, 2025, the Company received a deficiency letter from the Staff of Nasdaq notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500,000 in stockholders' equity for continued listing on the Nasdaq Capital Market (the "Stockholders' Equity Requirement”). Pursuant to the letter, the Company has 45 calendar days from November 21, 2025, to submit a plan to regain compliance and the Company intends to submit such a plan during this period. If it accepts the plan, Nasdaq can grant an extension of up t”